Form 4: Ligand Pharmaceuticals CFO Sells Shares
Insider Transaction (Form 4)
Octavio Espinoza, Chief Financial Officer of Ligand Pharmaceuticals Inc, sold 31,641 shares of common stock on August 12, 2026 for $292.06 per share.
Summary
- Option exercise/conversion: acquired 16,179 Common Stock at $52.84 ($854,898) on August 12, 2026; holds 43,875 after (Direct).
- Option exercise/conversion: acquired 2,074 Common Stock at $70.04 ($145,263) on August 12, 2026; holds 45,949 after (Direct).
- Option exercise/conversion: acquired 2,869 Common Stock at $55.75 ($159,947) on August 12, 2026; holds 48,818 after (Direct).
- Option exercise/conversion: acquired 7,171 Common Stock at $57.22 ($410,325) on August 12, 2026; holds 55,989 after (Direct).
- Option exercise/conversion: acquired 3,348 Common Stock at $68.74 ($230,142) on August 12, 2026; holds 59,337 after (Direct).
- Open-market sale: disposed of 31,641 Common Stock at $292.06 ($9,241,229) on August 12, 2026; holds 27,696 after (Direct).
- Option exercise/conversion: disposed of 2,869 Employee Stock Option (right to buy) on August 12, 2026 (Direct).
- Option exercise/conversion: disposed of 7,171 Employee Stock Option (right to buy) on August 12, 2026 (Direct).
- Option exercise/conversion: disposed of 16,179 Non-Qualified Stock Option (right to buy) on August 12, 2026 (Direct).
- Option exercise/conversion: disposed of 3,348 Non-Qualified Stock Option (right to buy) on August 12, 2026 (Direct).
- Option exercise/conversion: disposed of 2,074 Non-Qualified Stock Option (right to buy) on August 12, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $9,241,229 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Octavio Espinoza — Officer (Chief Financial Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-12 | Option exercise/conversion | Common Stock | 16,179 | $53 | $854.9K | 43,875 |
| 2026-08-12 | Option exercise/conversion | Common Stock | 2,074 | $70 | $145.3K | 45,949 |
| 2026-08-12 | Option exercise/conversion | Common Stock | 2,869 | $56 | $159.9K | 48,818 |
| 2026-08-12 | Option exercise/conversion | Common Stock | 7,171 | $57 | $410.3K | 55,989 |
| 2026-08-12 | Option exercise/conversion | Common Stock | 3,348 | $69 | $230.1K | 59,337 |
| 2026-08-12 | Open-market sale | Common Stock | 31,641 | $292 | $9.2M | 27,696 |
| 2026-08-12 | Option exercise/conversion | Employee Stock Option (right to buy) | 2,869 | — | — | 0 |
| 2026-08-12 | Option exercise/conversion | Employee Stock Option (right to buy) | 7,171 | — | — | 0 |
| 2026-08-12 | Option exercise/conversion | Non-Qualified Stock Option (right to buy) | 16,179 | — | — | 0 |
| 2026-08-12 | Option exercise/conversion | Non-Qualified Stock Option (right to buy) | 3,348 | — | — | 0 |
| 2026-08-12 | Option exercise/conversion | Non-Qualified Stock Option (right to buy) | 2,074 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-12 | Option exercise/conversion (16,179 shares) |
| 2026-08-12 | Option exercise/conversion (2,074 shares) |
| 2026-08-12 | Option exercise/conversion (2,869 shares) |
| 2026-08-12 | Option exercise/conversion (7,171 shares) |
| 2026-08-12 | Option exercise/conversion (3,348 shares) |
| 2026-08-12 | Open-market sale (31,641 shares) |
| 2026-08-12 | Option exercise/conversion (2,869 shares) |
| 2026-08-12 | Option exercise/conversion (7,171 shares) |
| 2026-08-12 | Option exercise/conversion (16,179 shares) |
| 2026-08-12 | Option exercise/conversion (3,348 shares) |
| 2026-08-12 | Option exercise/conversion (2,074 shares) |
Keywords
insider transaction, Form 4, LGND, LIGAND PHARMACEUTICALS INC, bearish, Octavio Espinoza
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.